Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis
暂无分享,去创建一个
S. Hill | S. Wiktor | S. Vogler | K. de Joncheere | P. Beyer | K. Tay-Teo | Swathi Iyengar
[1] S. Hamid,et al. Disparity in market prices for hepatitis C virus direct-acting drugs. , 2015, The Lancet. Global health.
[2] G. Dore,et al. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States , 2015, Annals of Internal Medicine.
[3] James Allison,et al. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. , 2015, Mayo Clinic proceedings.
[4] K. Bennett,et al. The Budget Impact of Hepatitis C Treatment in Ireland 2001-2012. , 2015, Irish medical journal.
[5] S. Ramani,et al. Access to critical medicines: When are compulsory licenses effective in price negotiations? , 2015, Social science & medicine.
[6] Adrian Towse,et al. European Union Pharmaceutical Markets: A Case for Differential Pricing? , 2015 .
[7] J. Rich,et al. A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System , 2015, Journal of Urban Health.
[8] Jason Grebely,et al. Mixed HCV infection and reinfection in people who inject drugs—impact on therapy , 2015, Nature Reviews Gastroenterology &Hepatology.
[9] Jagpreet Chhatwal,et al. Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States , 2015, Annals of Internal Medicine.
[10] Bernadette A. Thomas,et al. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.
[11] H. Razavi,et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. , 2014, Journal of hepatology.
[12] A. Branch,et al. Costs of telaprevir‐based triple therapy for hepatitis C: $189,000 per sustained virological response , 2014, Hepatology.
[13] L. Annemans,et al. Health Economic Data Requirements and Availability in the European Union: Results of a Survey Among 10 European Countries. , 2014, Value in health regional issues.
[14] Michał Jakubczyk,et al. Cost-effectiveness versus Cost-Utility Analyses: What Are the Motives Behind Using Each and How Do Their Results Differ?-A Polish Example. , 2014, Value in health regional issues.
[15] J. Tice,et al. The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection. , 2014, JAMA internal medicine.
[16] Riina Salupere,et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. , 2014, The New England journal of medicine.
[17] J. Montaner,et al. Income level and drug related harm among people who use injection drugs in a Canadian setting. , 2014, The International journal on drug policy.
[18] Sanjeev Arora,et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. , 2014, The New England journal of medicine.
[19] N. Ford,et al. Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] Francisco Cervantes,et al. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. , 2013, Blood.
[21] W. Kaplan,et al. Allocating scarce financial resources for HIV treatment: benchmarking prices of antiretroviral medicines in Latin America. , 2012, Health policy and planning.
[22] A. Bucsics,et al. Discounts and rebates granted to public payers for medicines in European countries , 2012, Southern med review.
[23] S. Saxena,et al. Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries , 2012, Epilepsia.
[24] G. Lauer,et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. , 2012, The Lancet. Infectious diseases.
[25] Karol Sikora,et al. Delivering affordable cancer care in high-income countries. , 2011, The Lancet. Oncology.
[26] D. Lavanchy. Evolving epidemiology of hepatitis C virus. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[27] A. Calmy,et al. Driving a decade of change: HIV/AIDS, patents and access to medicines for all , 2011, Journal of the International AIDS Society.
[28] A. Wolkoff,et al. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients , 2010, Hepatology.
[29] Ellen Diedrichsen,et al. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries , 2010, Journal of the International AIDS Society.
[30] D Ross-Degnan,et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis , 2009, The Lancet.
[31] M. Fried,et al. Side effects of therapy of hepatitis C and their management , 2002, Hepatology.
[32] T. Karin,et al. Hepatitis C Medicines: Technology and Market Landscape , 2015 .
[33] US health insurers say Gilead hepatitis C drug too costly. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] H. Leufkens,et al. Differences in external price referencing in Europe: a descriptive overview. , 2012, Health policy.
[35] Alan D. Lopez,et al. The Global Burden of Disease Study , 2003 .
[36] Lawrence L. Schembri,et al. Purchasing-Power Parity: Definition, Measurement, and Interpretation , 2002 .
[37] J. Gandhara,et al. Available , 1984 .
[38] Igi Global. : A state , 2022 .
[39] Country Reports on Human Rights Practices , 2022 .